Article in Clinical journal of the American Society of Nephrology : CJASN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Jincan ZanKidney Division, Key Laboratory of Kidney Disease, Peking University Institute of Nephrology, Peking University First Hospital, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China.
Jingyi LiKidney Division, Key Laboratory of Kidney Disease, Peking University Institute of Nephrology, Peking University First Hospital, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China.ORCID 0009-0007-7739-1184
Muh Geot WongThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0002-7575-9877
Dana KimThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0003-4611-5770
Sufang ShiKidney Division, Key Laboratory of Kidney Disease, Peking University Institute of Nephrology, Peking University First Hospital, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China.ORCID 0000-0002-8949-7054
Helen MonaghanThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0001-5369-178
Vlado PerkovicThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Jicheng LvKidney Division, Key Laboratory of Kidney Disease, Peking University Institute of Nephrology, Peking University First Hospital, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China.
Hong ZhangKidney Division, Key Laboratory of Kidney Disease, Peking University Institute of Nephrology, Peking University First Hospital, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China.
TESTING study biomarker group
Funding
Capital's Funds for Health Improvement and Research 2024-1-4073National Key Research and Development Program of China 2024YFC2511001&2024YFC2511004the National High level hospital clinical research funding (high quality clinical research project of Peking University First Hospital 2022CR80, 2022CX15
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy. · full record | OpenQuestion